US FDA News

top of page

iPharmaCenter

News | Blogs | Healthcare | Consulting

Contact: info@ipharmacenter.com

Home
Pharma
Healthcare News
Healthcare Policies
Disease News
Conferences
Others
- COVID-19
- Contact

Search

FDA Approves Novartis' Pluvicto for Earlier Treatment of Prostate Cancer | iPharmaCenter

ipharmaservices

Apr 3

0

Tevimbra Receives U.S. Approval for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy | iPharmaCenter

ipharmaservices

Mar 5

0

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

ipharmaservices

Feb 3

0

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

ipharmaservices

Jan 29

0

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

ipharmaservices

Jan 3

0

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

ipharmaservices

Dec 23, 2024

0

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

ipharmaservices

Oct 13, 2024

0

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

ipharmaservices

Oct 13, 2024

0

US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter

ipharmaservices

Oct 9, 2024

0

FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter

ipharmaservices

Aug 24, 2024

0

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

ipharmaservices

Aug 8, 2024

0

FDA Approved Sun Pharma's Leqselvi (deuruxolitinib) for Severe Alopecia Areata

ipharmaservices

Aug 8, 2024

0

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

ipharmaservices

Aug 5, 2024

0

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

ipharmaservices

Jul 4, 2024

0

Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter

ipharmaservices

Jun 20, 2024

0

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

ipharmaservices

Jun 19, 2024

0

FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

ipharmaservices

Jun 18, 2024

0

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

ipharmaservices

May 31, 2024

0

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

ipharmaservices

May 16, 2024

0

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

ipharmaservices

Apr 30, 2024

0

For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code.

Rephrase with Ginger (Cmd+⌥+E)

iPharmaCenter Telegran_edited.jpg

bottom of page